Global Nanomaterial-Based Adjuvants Vaccine Market Growth 2022-2028
As the global economy mends, the 2021 growth of Nanomaterial-Based Adjuvants Vaccine will have significant change from previous year. According to our latest study, the global Nanomaterial-Based Adjuvants Vaccine market size is USD million in 2022 from USD 57800 million in 2021, with a change of % between 2021 and 2022. The global Nanomaterial-Based Adjuvants Vaccine market size will reach USD 100990 million in 2028, growing at a CAGR of 8.3% over the analysis period.
The United States Nanomaterial-Based Adjuvants Vaccine market is expected at value of US$ million in 2021 and grow at approximately % CAGR during review period. China constitutes a % market for the global Nanomaterial-Based Adjuvants Vaccine market, reaching US$ million by the year 2028. As for the Europe Nanomaterial-Based Adjuvants Vaccine landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period. In APAC, the growth rates of other notable markets (Japan and South Korea) are projected to be at % and % respectively for the next 5-year period.
Global main Nanomaterial-Based Adjuvants Vaccine players cover Emergent BioSolutions, Sanofi, GlaxoSmithKline Biologicals, and Merck, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
This report presents a comprehensive overview, market shares, and growth opportunities of Nanomaterial-Based Adjuvants Vaccine market by product type, application, key manufacturers and key regions and countries.
Segmentation by type: breakdown data from 2017 to 2022, in Section 2.3; and forecast to 2028 in section 12.6
Aluminium Hydroxides
Aluminium Phosphate
Lipidosome
Others
Segmentation by application: breakdown data from 2017 to 2022, in Section 2.4; and forecast to 2028 in section 12.7.
Pneumococcus
Human Papilloma Virus
DTaP
Viral Hepatitis TypeA
Viral Hepatitis TypeB
SARS-CoV-2
Others
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the prominent manufacturers in this market, include
Emergent BioSolutions
Sanofi
GlaxoSmithKline Biologicals
Merck
Pfizer
Novartis
Moderna
Frequently Asked Questions
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
- By Type
- By Application
- By Region
- By Country
- By Manufacturer
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Nanomaterial-Based Adjuvants Vaccine Annual Sales 2017-2028
2.1.2 World Current & Future Analysis for Nanomaterial-Based Adjuvants Vaccine by Geographic Region, 2017, 2022 & 2028
2.1.3 World Current & Future Analysis for Nanomaterial-Based Adjuvants Vaccine by Country/Region, 2017, 2022 & 2028
2.2 Nanomaterial-Based Adjuvants Vaccine Segment by Type
2.2.1 Aluminium Hydroxides
2.2.2 Aluminium Phosphate
2.2.3 Lipidosome
2.2.4 Others
2.3 Nanomaterial-Based Adjuvants Vaccine Sales by Type
2.3.1 Global Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Type (2017-2022)
2.3.2 Global Nanomaterial-Based Adjuvants Vaccine Revenue and Market Share by Type (2017-2022)
2.3.3 Global Nanomaterial-Based Adjuvants Vaccine Sale Price by Type (2017-2022)
2.4 Nanomaterial-Based Adjuvants Vaccine Segment by Application
2.4.1 Pneumococcus
2.4.2 Human Papilloma Virus
2.4.3 DTaP
2.4.4 Viral Hepatitis TypeA
2.4.5 Viral Hepatitis TypeB
2.4.6 SARS-CoV-2
2.4.7 Others
2.5 Nanomaterial-Based Adjuvants Vaccine Sales by Application
2.5.1 Global Nanomaterial-Based Adjuvants Vaccine Sale Market Share by Application (2017-2022)
2.5.2 Global Nanomaterial-Based Adjuvants Vaccine Revenue and Market Share by Application (2017-2022)
2.5.3 Global Nanomaterial-Based Adjuvants Vaccine Sale Price by Application (2017-2022)
3 Global Nanomaterial-Based Adjuvants Vaccine by Company
3.1 Global Nanomaterial-Based Adjuvants Vaccine Breakdown Data by Company
3.1.1 Global Nanomaterial-Based Adjuvants Vaccine Annual Sales by Company (2020-2022)
3.1.2 Global Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Company (2020-2022)
3.2 Global Nanomaterial-Based Adjuvants Vaccine Annual Revenue by Company (2020-2022)
3.2.1 Global Nanomaterial-Based Adjuvants Vaccine Revenue by Company (2020-2022)
3.2.2 Global Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Company (2020-2022)
3.3 Global Nanomaterial-Based Adjuvants Vaccine Sale Price by Company
3.4 Key Manufacturers Nanomaterial-Based Adjuvants Vaccine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Nanomaterial-Based Adjuvants Vaccine Product Location Distribution
3.4.2 Players Nanomaterial-Based Adjuvants Vaccine Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Nanomaterial-Based Adjuvants Vaccine by Geographic Region
4.1 World Historic Nanomaterial-Based Adjuvants Vaccine Market Size by Geographic Region (2017-2022)
4.1.1 Global Nanomaterial-Based Adjuvants Vaccine Annual Sales by Geographic Region (2017-2022)
4.1.2 Global Nanomaterial-Based Adjuvants Vaccine Annual Revenue by Geographic Region
4.2 World Historic Nanomaterial-Based Adjuvants Vaccine Market Size by Country/Region (2017-2022)
4.2.1 Global Nanomaterial-Based Adjuvants Vaccine Annual Sales by Country/Region (2017-2022)
4.2.2 Global Nanomaterial-Based Adjuvants Vaccine Annual Revenue by Country/Region
4.3 Americas Nanomaterial-Based Adjuvants Vaccine Sales Growth
4.4 APAC Nanomaterial-Based Adjuvants Vaccine Sales Growth
4.5 Europe Nanomaterial-Based Adjuvants Vaccine Sales Growth
4.6 Middle East & Africa Nanomaterial-Based Adjuvants Vaccine Sales Growth
5 Americas
5.1 Americas Nanomaterial-Based Adjuvants Vaccine Sales by Country
5.1.1 Americas Nanomaterial-Based Adjuvants Vaccine Sales by Country (2017-2022)
5.1.2 Americas Nanomaterial-Based Adjuvants Vaccine Revenue by Country (2017-2022)
5.2 Americas Nanomaterial-Based Adjuvants Vaccine Sales by Type
5.3 Americas Nanomaterial-Based Adjuvants Vaccine Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Nanomaterial-Based Adjuvants Vaccine Sales by Region
6.1.1 APAC Nanomaterial-Based Adjuvants Vaccine Sales by Region (2017-2022)
6.1.2 APAC Nanomaterial-Based Adjuvants Vaccine Revenue by Region (2017-2022)
6.2 APAC Nanomaterial-Based Adjuvants Vaccine Sales by Type
6.3 APAC Nanomaterial-Based Adjuvants Vaccine Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Nanomaterial-Based Adjuvants Vaccine by Country
7.1.1 Europe Nanomaterial-Based Adjuvants Vaccine Sales by Country (2017-2022)
7.1.2 Europe Nanomaterial-Based Adjuvants Vaccine Revenue by Country (2017-2022)
7.2 Europe Nanomaterial-Based Adjuvants Vaccine Sales by Type
7.3 Europe Nanomaterial-Based Adjuvants Vaccine Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Nanomaterial-Based Adjuvants Vaccine by Country
8.1.1 Middle East & Africa Nanomaterial-Based Adjuvants Vaccine Sales by Country (2017-2022)
8.1.2 Middle East & Africa Nanomaterial-Based Adjuvants Vaccine Revenue by Country (2017-2022)
8.2 Middle East & Africa Nanomaterial-Based Adjuvants Vaccine Sales by Type
8.3 Middle East & Africa Nanomaterial-Based Adjuvants Vaccine Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Nanomaterial-Based Adjuvants Vaccine
10.3 Manufacturing Process Analysis of Nanomaterial-Based Adjuvants Vaccine
10.4 Industry Chain Structure of Nanomaterial-Based Adjuvants Vaccine
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Nanomaterial-Based Adjuvants Vaccine Distributors
11.3 Nanomaterial-Based Adjuvants Vaccine Customer
12 World Forecast Review for Nanomaterial-Based Adjuvants Vaccine by Geographic Region
12.1 Global Nanomaterial-Based Adjuvants Vaccine Market Size Forecast by Region
12.1.1 Global Nanomaterial-Based Adjuvants Vaccine Forecast by Region (2023-2028)
12.1.2 Global Nanomaterial-Based Adjuvants Vaccine Annual Revenue Forecast by Region (2023-2028)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Nanomaterial-Based Adjuvants Vaccine Forecast by Type
12.7 Global Nanomaterial-Based Adjuvants Vaccine Forecast by Application
13 Key Players Analysis
13.1 Emergent BioSolutions
13.1.1 Emergent BioSolutions Company Information
13.1.2 Emergent BioSolutions Nanomaterial-Based Adjuvants Vaccine Product Offered
13.1.3 Emergent BioSolutions Nanomaterial-Based Adjuvants Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.1.4 Emergent BioSolutions Main Business Overview
13.1.5 Emergent BioSolutions Latest Developments
13.2 Sanofi
13.2.1 Sanofi Company Information
13.2.2 Sanofi Nanomaterial-Based Adjuvants Vaccine Product Offered
13.2.3 Sanofi Nanomaterial-Based Adjuvants Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.2.4 Sanofi Main Business Overview
13.2.5 Sanofi Latest Developments
13.3 GlaxoSmithKline Biologicals
13.3.1 GlaxoSmithKline Biologicals Company Information
13.3.2 GlaxoSmithKline Biologicals Nanomaterial-Based Adjuvants Vaccine Product Offered
13.3.3 GlaxoSmithKline Biologicals Nanomaterial-Based Adjuvants Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.3.4 GlaxoSmithKline Biologicals Main Business Overview
13.3.5 GlaxoSmithKline Biologicals Latest Developments
13.4 Merck
13.4.1 Merck Company Information
13.4.2 Merck Nanomaterial-Based Adjuvants Vaccine Product Offered
13.4.3 Merck Nanomaterial-Based Adjuvants Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.4.4 Merck Main Business Overview
13.4.5 Merck Latest Developments
13.5 Pfizer
13.5.1 Pfizer Company Information
13.5.2 Pfizer Nanomaterial-Based Adjuvants Vaccine Product Offered
13.5.3 Pfizer Nanomaterial-Based Adjuvants Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.5.4 Pfizer Main Business Overview
13.5.5 Pfizer Latest Developments
13.6 Novartis
13.6.1 Novartis Company Information
13.6.2 Novartis Nanomaterial-Based Adjuvants Vaccine Product Offered
13.6.3 Novartis Nanomaterial-Based Adjuvants Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.6.4 Novartis Main Business Overview
13.6.5 Novartis Latest Developments
13.7 Moderna
13.7.1 Moderna Company Information
13.7.2 Moderna Nanomaterial-Based Adjuvants Vaccine Product Offered
13.7.3 Moderna Nanomaterial-Based Adjuvants Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.7.4 Moderna Main Business Overview
13.7.5 Moderna Latest Developments
14 Research Findings and Conclusion
List of Tables
Table 1. Nanomaterial-Based Adjuvants Vaccine Annual Sales CAGR by Geographic Region (2017, 2022 & 2028) & ($ millions)
Table 2. Nanomaterial-Based Adjuvants Vaccine Annual Sales CAGR by Country/Region (2017, 2022 & 2028) & ($ millions)
Table 3. Major Players of Aluminium Hydroxides
Table 4. Major Players of Aluminium Phosphate
Table 5. Major Players of Lipidosome
Table 6. Major Players of Others
Table 7. Global Nanomaterial-Based Adjuvants Vaccine Sales by Type (2017-2022) & (M Doses)
Table 8. Global Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Type (2017-2022)
Table 9. Global Nanomaterial-Based Adjuvants Vaccine Revenue by Type (2017-2022) & ($ million)
Table 10. Global Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Type (2017-2022)
Table 11. Global Nanomaterial-Based Adjuvants Vaccine Sale Price by Type (2017-2022) & (US$/Dose)
Table 12. Global Nanomaterial-Based Adjuvants Vaccine Sales by Application (2017-2022) & (M Doses)
Table 13. Global Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Application (2017-2022)
Table 14. Global Nanomaterial-Based Adjuvants Vaccine Revenue by Application (2017-2022)
Table 15. Global Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Application (2017-2022)
Table 16. Global Nanomaterial-Based Adjuvants Vaccine Sale Price by Application (2017-2022) & (US$/Dose)
Table 17. Global Nanomaterial-Based Adjuvants Vaccine Sales by Company (2020-2022) & (M Doses)
Table 18. Global Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Company (2020-2022)
Table 19. Global Nanomaterial-Based Adjuvants Vaccine Revenue by Company (2020-2022) ($ Millions)
Table 20. Global Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Company (2020-2022)
Table 21. Global Nanomaterial-Based Adjuvants Vaccine Sale Price by Company (2020-2022) & (US$/Dose)
Table 22. Key Manufacturers Nanomaterial-Based Adjuvants Vaccine Producing Area Distribution and Sales Area
Table 23. Players Nanomaterial-Based Adjuvants Vaccine Products Offered
Table 24. Nanomaterial-Based Adjuvants Vaccine Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
Table 25. New Products and Potential Entrants
Table 26. Mergers & Acquisitions, Expansion
Table 27. Global Nanomaterial-Based Adjuvants Vaccine Sales by Geographic Region (2017-2022) & (M Doses)
Table 28. Global Nanomaterial-Based Adjuvants Vaccine Sales Market Share Geographic Region (2017-2022)
Table 29. Global Nanomaterial-Based Adjuvants Vaccine Revenue by Geographic Region (2017-2022) & ($ millions)
Table 30. Global Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Geographic Region (2017-2022)
Table 31. Global Nanomaterial-Based Adjuvants Vaccine Sales by Country/Region (2017-2022) & (M Doses)
Table 32. Global Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Country/Region (2017-2022)
Table 33. Global Nanomaterial-Based Adjuvants Vaccine Revenue by Country/Region (2017-2022) & ($ millions)
Table 34. Global Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Country/Region (2017-2022)
Table 35. Americas Nanomaterial-Based Adjuvants Vaccine Sales by Country (2017-2022) & (M Doses)
Table 36. Americas Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Country (2017-2022)
Table 37. Americas Nanomaterial-Based Adjuvants Vaccine Revenue by Country (2017-2022) & ($ Millions)
Table 38. Americas Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Country (2017-2022)
Table 39. Americas Nanomaterial-Based Adjuvants Vaccine Sales by Type (2017-2022) & (M Doses)
Table 40. Americas Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Type (2017-2022)
Table 41. Americas Nanomaterial-Based Adjuvants Vaccine Sales by Application (2017-2022) & (M Doses)
Table 42. Americas Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Application (2017-2022)
Table 43. APAC Nanomaterial-Based Adjuvants Vaccine Sales by Region (2017-2022) & (M Doses)
Table 44. APAC Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Region (2017-2022)
Table 45. APAC Nanomaterial-Based Adjuvants Vaccine Revenue by Region (2017-2022) & ($ Millions)
Table 46. APAC Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Region (2017-2022)
Table 47. APAC Nanomaterial-Based Adjuvants Vaccine Sales by Type (2017-2022) & (M Doses)
Table 48. APAC Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Type (2017-2022)
Table 49. APAC Nanomaterial-Based Adjuvants Vaccine Sales by Application (2017-2022) & (M Doses)
Table 50. APAC Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Application (2017-2022)
Table 51. Europe Nanomaterial-Based Adjuvants Vaccine Sales by Country (2017-2022) & (M Doses)
Table 52. Europe Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Country (2017-2022)
Table 53. Europe Nanomaterial-Based Adjuvants Vaccine Revenue by Country (2017-2022) & ($ Millions)
Table 54. Europe Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Country (2017-2022)
Table 55. Europe Nanomaterial-Based Adjuvants Vaccine Sales by Type (2017-2022) & (M Doses)
Table 56. Europe Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Type (2017-2022)
Table 57. Europe Nanomaterial-Based Adjuvants Vaccine Sales by Application (2017-2022) & (M Doses)
Table 58. Europe Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Application (2017-2022)
Table 59. Middle East & Africa Nanomaterial-Based Adjuvants Vaccine Sales by Country (2017-2022) & (M Doses)
Table 60. Middle East & Africa Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Country (2017-2022)
Table 61. Middle East & Africa Nanomaterial-Based Adjuvants Vaccine Revenue by Country (2017-2022) & ($ Millions)
Table 62. Middle East & Africa Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Country (2017-2022)
Table 63. Middle East & Africa Nanomaterial-Based Adjuvants Vaccine Sales by Type (2017-2022) & (M Doses)
Table 64. Middle East & Africa Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Type (2017-2022)
Table 65. Middle East & Africa Nanomaterial-Based Adjuvants Vaccine Sales by Application (2017-2022) & (M Doses)
Table 66. Middle East & Africa Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Application (2017-2022)
Table 67. Key Market Drivers & Growth Opportunities of Nanomaterial-Based Adjuvants Vaccine
Table 68. Key Market Challenges & Risks of Nanomaterial-Based Adjuvants Vaccine
Table 69. Key Industry Trends of Nanomaterial-Based Adjuvants Vaccine
Table 70. Nanomaterial-Based Adjuvants Vaccine Raw Material
Table 71. Key Suppliers of Raw Materials
Table 72. Nanomaterial-Based Adjuvants Vaccine Distributors List
Table 73. Nanomaterial-Based Adjuvants Vaccine Customer List
Table 74. Global Nanomaterial-Based Adjuvants Vaccine Sales Forecast by Region (2023-2028) & (M Doses)
Table 75. Global Nanomaterial-Based Adjuvants Vaccine Sales Market Forecast by Region
Table 76. Global Nanomaterial-Based Adjuvants Vaccine Revenue Forecast by Region (2023-2028) & ($ millions)
Table 77. Global Nanomaterial-Based Adjuvants Vaccine Revenue Market Share Forecast by Region (2023-2028)
Table 78. Americas Nanomaterial-Based Adjuvants Vaccine Sales Forecast by Country (2023-2028) & (M Doses)
Table 79. Americas Nanomaterial-Based Adjuvants Vaccine Revenue Forecast by Country (2023-2028) & ($ millions)
Table 80. APAC Nanomaterial-Based Adjuvants Vaccine Sales Forecast by Region (2023-2028) & (M Doses)
Table 81. APAC Nanomaterial-Based Adjuvants Vaccine Revenue Forecast by Region (2023-2028) & ($ millions)
Table 82. Europe Nanomaterial-Based Adjuvants Vaccine Sales Forecast by Country (2023-2028) & (M Doses)
Table 83. Europe Nanomaterial-Based Adjuvants Vaccine Revenue Forecast by Country (2023-2028) & ($ millions)
Table 84. Middle East & Africa Nanomaterial-Based Adjuvants Vaccine Sales Forecast by Country (2023-2028) & (M Doses)
Table 85. Middle East & Africa Nanomaterial-Based Adjuvants Vaccine Revenue Forecast by Country (2023-2028) & ($ millions)
Table 86. Global Nanomaterial-Based Adjuvants Vaccine Sales Forecast by Type (2023-2028) & (M Doses)
Table 87. Global Nanomaterial-Based Adjuvants Vaccine Sales Market Share Forecast by Type (2023-2028)
Table 88. Global Nanomaterial-Based Adjuvants Vaccine Revenue Forecast by Type (2023-2028) & ($ Millions)
Table 89. Global Nanomaterial-Based Adjuvants Vaccine Revenue Market Share Forecast by Type (2023-2028)
Table 90. Global Nanomaterial-Based Adjuvants Vaccine Sales Forecast by Application (2023-2028) & (M Doses)
Table 91. Global Nanomaterial-Based Adjuvants Vaccine Sales Market Share Forecast by Application (2023-2028)
Table 92. Global Nanomaterial-Based Adjuvants Vaccine Revenue Forecast by Application (2023-2028) & ($ Millions)
Table 93. Global Nanomaterial-Based Adjuvants Vaccine Revenue Market Share Forecast by Application (2023-2028)
Table 94. Emergent BioSolutions Basic Information, Nanomaterial-Based Adjuvants Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 95. Emergent BioSolutions Nanomaterial-Based Adjuvants Vaccine Product Offered
Table 96. Emergent BioSolutions Nanomaterial-Based Adjuvants Vaccine Sales (M Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2020-2022)
Table 97. Emergent BioSolutions Main Business
Table 98. Emergent BioSolutions Latest Developments
Table 99. Sanofi Basic Information, Nanomaterial-Based Adjuvants Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 100. Sanofi Nanomaterial-Based Adjuvants Vaccine Product Offered
Table 101. Sanofi Nanomaterial-Based Adjuvants Vaccine Sales (M Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2020-2022)
Table 102. Sanofi Main Business
Table 103. Sanofi Latest Developments
Table 104. GlaxoSmithKline Biologicals Basic Information, Nanomaterial-Based Adjuvants Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 105. GlaxoSmithKline Biologicals Nanomaterial-Based Adjuvants Vaccine Product Offered
Table 106. GlaxoSmithKline Biologicals Nanomaterial-Based Adjuvants Vaccine Sales (M Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2020-2022)
Table 107. GlaxoSmithKline Biologicals Main Business
Table 108. GlaxoSmithKline Biologicals Latest Developments
Table 109. Merck Basic Information, Nanomaterial-Based Adjuvants Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 110. Merck Nanomaterial-Based Adjuvants Vaccine Product Offered
Table 111. Merck Nanomaterial-Based Adjuvants Vaccine Sales (M Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2020-2022)
Table 112. Merck Main Business
Table 113. Merck Latest Developments
Table 114. Pfizer Basic Information, Nanomaterial-Based Adjuvants Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 115. Pfizer Nanomaterial-Based Adjuvants Vaccine Product Offered
Table 116. Pfizer Nanomaterial-Based Adjuvants Vaccine Sales (M Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2020-2022)
Table 117. Pfizer Main Business
Table 118. Pfizer Latest Developments
Table 119. Novartis Basic Information, Nanomaterial-Based Adjuvants Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 120. Novartis Nanomaterial-Based Adjuvants Vaccine Product Offered
Table 121. Novartis Nanomaterial-Based Adjuvants Vaccine Sales (M Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2020-2022)
Table 122. Novartis Main Business
Table 123. Novartis Latest Developments
Table 124. Moderna Basic Information, Nanomaterial-Based Adjuvants Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 125. Moderna Nanomaterial-Based Adjuvants Vaccine Product Offered
Table 126. Moderna Nanomaterial-Based Adjuvants Vaccine Sales (M Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2020-2022)
Table 127. Moderna Main Business
Table 128. Moderna Latest Developments
List of Figures
Figure 1. Picture of Nanomaterial-Based Adjuvants Vaccine
Figure 2. Nanomaterial-Based Adjuvants Vaccine Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Nanomaterial-Based Adjuvants Vaccine Sales Growth Rate 2017-2028 (M Doses)
Figure 7. Global Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate 2017-2028 ($ Millions)
Figure 8. Nanomaterial-Based Adjuvants Vaccine Sales by Region (2021 & 2028) & ($ millions)
Figure 9. Product Picture of Aluminium Hydroxides
Figure 10. Product Picture of Aluminium Phosphate
Figure 11. Product Picture of Lipidosome
Figure 12. Product Picture of Others
Figure 13. Global Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Type in 2021
Figure 14. Global Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Type (2017-2022)
Figure 15. Nanomaterial-Based Adjuvants Vaccine Consumed in Pneumococcus
Figure 16. Global Nanomaterial-Based Adjuvants Vaccine Market: Pneumococcus (2017-2022) & (M Doses)
Figure 17. Nanomaterial-Based Adjuvants Vaccine Consumed in Human Papilloma Virus
Figure 18. Global Nanomaterial-Based Adjuvants Vaccine Market: Human Papilloma Virus (2017-2022) & (M Doses)
Figure 19. Nanomaterial-Based Adjuvants Vaccine Consumed in DTaP
Figure 20. Global Nanomaterial-Based Adjuvants Vaccine Market: DTaP (2017-2022) & (M Doses)
Figure 21. Nanomaterial-Based Adjuvants Vaccine Consumed in Viral Hepatitis TypeA
Figure 22. Global Nanomaterial-Based Adjuvants Vaccine Market: Viral Hepatitis TypeA (2017-2022) & (M Doses)
Figure 23. Nanomaterial-Based Adjuvants Vaccine Consumed in Viral Hepatitis TypeB
Figure 24. Global Nanomaterial-Based Adjuvants Vaccine Market: Viral Hepatitis TypeB (2017-2022) & (M Doses)
Figure 25. Nanomaterial-Based Adjuvants Vaccine Consumed in SARS-CoV-2
Figure 26. Global Nanomaterial-Based Adjuvants Vaccine Market: SARS-CoV-2 (2017-2022) & (M Doses)
Figure 27. Nanomaterial-Based Adjuvants Vaccine Consumed in Others
Figure 28. Global Nanomaterial-Based Adjuvants Vaccine Market: Others (2017-2022) & (M Doses)
Figure 29. Global Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Application (2017-2022)
Figure 30. Global Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Application in 2021
Figure 31. Nanomaterial-Based Adjuvants Vaccine Revenue Market by Company in 2021 ($ Million)
Figure 32. Global Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Company in 2021
Figure 33. Global Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Geographic Region (2017-2022)
Figure 34. Global Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Geographic Region in 2021
Figure 35. Global Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Region (2017-2022)
Figure 36. Global Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Country/Region in 2021
Figure 37. Americas Nanomaterial-Based Adjuvants Vaccine Sales 2017-2022 (M Doses)
Figure 38. Americas Nanomaterial-Based Adjuvants Vaccine Revenue 2017-2022 ($ Millions)
Figure 39. APAC Nanomaterial-Based Adjuvants Vaccine Sales 2017-2022 (M Doses)
Figure 40. APAC Nanomaterial-Based Adjuvants Vaccine Revenue 2017-2022 ($ Millions)
Figure 41. Europe Nanomaterial-Based Adjuvants Vaccine Sales 2017-2022 (M Doses)
Figure 42. Europe Nanomaterial-Based Adjuvants Vaccine Revenue 2017-2022 ($ Millions)
Figure 43. Middle East & Africa Nanomaterial-Based Adjuvants Vaccine Sales 2017-2022 (M Doses)
Figure 44. Middle East & Africa Nanomaterial-Based Adjuvants Vaccine Revenue 2017-2022 ($ Millions)
Figure 45. Americas Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Country in 2021
Figure 46. Americas Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Country in 2021
Figure 47. United States Nanomaterial-Based Adjuvants Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 48. Canada Nanomaterial-Based Adjuvants Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 49. Mexico Nanomaterial-Based Adjuvants Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 50. Brazil Nanomaterial-Based Adjuvants Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 51. APAC Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Region in 2021
Figure 52. APAC Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Regions in 2021
Figure 53. China Nanomaterial-Based Adjuvants Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 54. Japan Nanomaterial-Based Adjuvants Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 55. South Korea Nanomaterial-Based Adjuvants Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 56. Southeast Asia Nanomaterial-Based Adjuvants Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 57. India Nanomaterial-Based Adjuvants Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 58. Australia Nanomaterial-Based Adjuvants Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 59. Europe Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Country in 2021
Figure 60. Europe Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Country in 2021
Figure 61. Germany Nanomaterial-Based Adjuvants Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 62. France Nanomaterial-Based Adjuvants Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 63. UK Nanomaterial-Based Adjuvants Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 64. Italy Nanomaterial-Based Adjuvants Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 65. Russia Nanomaterial-Based Adjuvants Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 66. Middle East & Africa Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Country in 2021
Figure 67. Middle East & Africa Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Country in 2021
Figure 68. Egypt Nanomaterial-Based Adjuvants Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 69. South Africa Nanomaterial-Based Adjuvants Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 70. Israel Nanomaterial-Based Adjuvants Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 71. Turkey Nanomaterial-Based Adjuvants Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 72. GCC Country Nanomaterial-Based Adjuvants Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 73. Manufacturing Cost Structure Analysis of Nanomaterial-Based Adjuvants Vaccine in 2021
Figure 74. Manufacturing Process Analysis of Nanomaterial-Based Adjuvants Vaccine
Figure 75. Industry Chain Structure of Nanomaterial-Based Adjuvants Vaccine
Figure 76. Channels of Distribution
Figure 77. Distributors Profiles
